Edwards Lifesciences Co. (NYSE:EW) Shares Sold by AtonRa Partners

AtonRa Partners decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,789 shares of the medical research company’s stock after selling 312 shares during the quarter. AtonRa Partners’ holdings in Edwards Lifesciences were worth $213,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Nordea Investment Management AB boosted its holdings in Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after acquiring an additional 1,488,791 shares during the period. Telos Capital Management Inc. boosted its stake in shares of Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC increased its stake in Edwards Lifesciences by 5,092.4% during the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after buying an additional 12,069 shares during the period. Versor Investments LP lifted its holdings in Edwards Lifesciences by 83.3% during the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after buying an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $1,587,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.68 during midday trading on Tuesday, hitting $85.27. 440,716 shares of the company’s stock were exchanged, compared to its average volume of 3,798,306. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The stock has a market cap of $51.33 billion, a price-to-earnings ratio of 37.05, a price-to-earnings-growth ratio of 4.28 and a beta of 1.05. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm’s 50 day simple moving average is $90.27 and its 200 day simple moving average is $79.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Equities research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Buying and Selling

In other news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the transaction, the vice president now owns 17,213 shares in the company, valued at $1,566,038.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares in the company, valued at $2,980,774.68. The disclosure for this sale can be found here. Insiders sold a total of 194,004 shares of company stock valued at $17,166,254 over the last three months. 1.27% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on EW shares. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Piper Sandler increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday. Evercore ISI lowered their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Finally, Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.